1 / 14

by Shyama V. Ramani a And Augustin Maria b , Mahesh Ravi c , Preethi Pradhan d ,

The Indian Biotech Segment of the Indian Pharmaceuticals Industry in the post TRIPS world. by Shyama V. Ramani a And Augustin Maria b , Mahesh Ravi c , Preethi Pradhan d , a INRA, TecKnowMetrix, and Hi-Tide. b Ecole des Mines, Paris c Hi-Tide. d U-Berkeley and UPMF/Grenoble.

mckenzie-joyce
Download Presentation

by Shyama V. Ramani a And Augustin Maria b , Mahesh Ravi c , Preethi Pradhan d ,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Indian Biotech Segment of the Indian Pharmaceuticals Industry in the post TRIPS world by Shyama V. Ramania And Augustin Mariab, Mahesh Ravic,Preethi Pradhand , a INRA, TecKnowMetrix, and Hi-Tide. b Ecole des Mines, Paris c Hi-Tide. d U-Berkeley and UPMF/Grenoble Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  2. Innovation is a cumulative process First Innovator Subsequent Innovator Spillovers Challenge of the IPR system : How to reward both first and subsequent innovators? Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  3. Impact on “producers of technology” PRODUCTPATENTS Broad Patent Protection More incentives for First Innovators PROCESSPATENTS Narrow Patent Protection More incentives for Subsequent Innovators Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  4. Paris Convention 1883 = Country specific IPR TRIPS = NO more Country specific IPR Homogenization of scope of IPR over all countries Eventually some form of product patents For countries like INDIA, TRIPS= broadening of patent scope Shifting of Incentives from Second innovators to First ones Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  5. The Indian context PRODUCT PATENT REGIME : 1947-1970 • Indian Patent and Design Law of 1911 • First Crisis = Food ----- Solution = Green Revolution. • Second Crisis = Access to health care • Access to health = Access to basic medicines. • Sufficient quantities must be available. • Insufficient supply (Multinationals and Public Sector). • Pricing Policy and the “License Raj”. Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  6. Changes in IPR : 1970 • For Food and Drugs : Process patents and not product patents. • =Narrowing of the IPR system • Not viewed as likely to have impact by the multinationals who were the market leaders. • Tremendous impact. Indian pharmaceutical developed. Fledgling Indian health care system developed. Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  7. Types of Indian firms in the biopharmaceutical sector • Entrants • Integrated pharma firms • Diagnostic reagents & Vaccine manf. • Enzyme manf. • IT Firms Dedicated biotech firms Start-ups by labs Start-ups by ind Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  8. Impact of “incentive effect” on former second innovators or developing country firms Strategies Available now Import innovations Invest in creation of first innovations Invest in creation of second innovations Or non-patented innovations For developed countries Join as part of the division of labour chain in innovation creation by developed country firms. For developing countries Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  9. Impact of “incentive effect” on first innovators or developed country firms • Good investment climate; • Good Business climate; • Access to correct and credible information; • Credible dispute settlement institutions • Higher Foreign investment; • More technology transactions; Strong IPR + TRIPS Does this exist? So will this happen? Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  10. Impact of TRIPS (1/2) • Biggest focus : Bio-generics. • Indian firms cannot tackle world market. • Money spinner : Licensing to foreign firms. No incentive effect of TRIPS • Active service providers to Western multinationals in the creation of innovations • Part of the international division of labour No incentive effect of TRIPS Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  11. Impact of TRIPS (2/2) • New Drug creation. • If for international market patented in USA. • If for local market/tropical diseases not based on rationality of profit/rent/quasi rent maximization. No incentive effect of TRIPS • Entry strategies of foreign firms • Subsidiary, Joint venture, license • Main problems are identification of partners (adverse selection) and ensuring commitment (moral hazard) No incentive effect of TRIPS Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  12. Final Choices of Indian firms 3rd choice Import innovations 1st choice 2nd choice Invest in creation of first innovations Invest in creation of second innovations Or off-patented innovations For developed countries Join as part of the “division of labour” chain in innovation creation by developed country firms. For developing countries Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  13. View of Developed country firms • Good investment climate; • Good Business climate; • Access to correct and credible information; • Credible dispute settlement institutions • Higher Foreign investment; • More technology transactions; Strong IPR + TRIPS HAS TO IMROVE So will this happen? ????? Depends????? Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

  14. Proposals for Reform Agency to handle international litigations on tech. transactions • Open source literature • A non-profit association which collects data and conducts analysis • Motivation for Hi-Tide A Sachs-type institute at the international level coordinated and financially supported by both developing country and developed country partners Reperes sur l'innovation en Inde, 3 juin 2004, Shyama V. Ramani.

More Related